This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
PROfound
VISION Trial
mHSPC
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
CONDOR Trial
OSPREY Trial
Bladder Cancer
Bladder Cancer Detection
ADSTILADRIN
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
ECLIPSE
ESCAPE
FORT
NRG-GU 0101
Masofaniten (EPI-7386)
METANOVA
RTIRE
SHORTER
Right Side
PCCTC
DORA
IRONMAN
PROMISE
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Petros Grivas, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Sumanta (Monty) Kumar Pal, MD
Jaime Landman, MD
Prostate Cancer
Advanced Prostate Cancer
Alicia Morgans, MD, MPH
CRPC with Bone Metastases
Rana R. McKay, MD
Imaging Center
Phillip Koo, MD
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
mHSPC
Alicia Morgans, MD, MPH
nmCRPC
Alicia Morgans, MD, MPH
PSMA-Targeted Therapy
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular, Penile, and Rare GU Malignancies
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SESAUA 2024
Southern CA GU Cancer Research Forum 2024
AUA Urology Advocacy Summit 2024
ASCO GU 2024
2024 UCSF-UCLA PSMA Conference
SUO 2023
All Conferences
View All
PCF
UroToday Home
Video Lectures
ASCO GU 2021 Prostate Cancer
ASCO GU 2021 Prostate Cancer VL
Search
Clear
Most recent
Most hits
Most likes
Most dislikes
Title alphabetical
Recently modified
Recently viewed
Author alphabetical
Random
10
20
30
40
50
Impact of Concomitant Prostate Cancer Therapy of Relugolix in Men with Advanced Prostate Cancer - Daniel J. George
Details
Daniel George, MD, and Neal Shore, MD, FACS, co-investigators of the Phase III HERO Trial join Alicia Morgans, MD, MPH recapping the 2021 GU ASCO analysis that Daniel George presented on the efficacy and safety of relugolix vs leuprolide in men with advanced prostate cancer. This was a subgroup analysis assessing the impact of concomitant prostate cancer therapy on the safety and efficacy of the o...
IPATential150 Trial in Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Cora Sternberg
Details
Ipatasertib is a novel oral anti-cancer agent, under investigation in prostate and breast cancers. It is an orally administered agent designed to target three isoforms of AKT (protein kinase B), in order to block the PI3 Kinase/AKT signaling pathway. This pathway is known to contribute to prostate cancer carcinogenesis and also potentially in the resistance to anti-androgen therapies. At the ESMO...
Nivolumab Plus Docetaxel for Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer from CheckMate 9KD Arm B, - Karim Fizazi
Details
Karim Fizazi joins Alicia Morgans to discuss the final analysis results for Arm B of the CheckMate 9KD trial presented at the 2021 American Society of Clinical Oncology Genitourinary Cancers annual meeting (ASCO GU). CheckMate 9KD is a phase 2 trial of nivolumab (NIVO) in combination with rucaparib, docetaxel (DOCE), or enzalutamide for patients with metastatic castration-resistant prostate cancer...
Sequential Radium-223 Treatment of mCRPC That Progressed After First-Line Novel Antihormonal Therapy, A Real-World Clinical Outcomes Study - Oliver Sartor
Details
Oliver Sartor, MD joins Alicia Morgans, MD, MPH to discuss a real-world clinical outcomes study of sequential novel antihormonal therapy (abiraterone or enzalutamide) or radium-223 (Ra-223) treatment of metastatic castration-resistant prostate cancer (mCRPC) that progressed after first-line NAH. This data is taken from the real world reports in the Flatiron Registry. Dr. Sartor presented this data...
Comparing Lutetium-PSMA Vs. Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer (mCRPC) - Thera-P Trial - Michael Hofman
Details
Michael Hofman joins Alicia Morgans providing updated results from the TheraP clinical trial from data reported at the 2021 ASCO GU meeting. TheraP is the first randomized trial comparing 177Lu-PSMA-617 (Lu-PSMA), a novel radioactive treatment, to the current standard-of-care chemotherapy called cabazitaxel for men with metastatic castration-resistant prostate cancer. These men had disease that ha...
Start
Prev
1
2
3
Next
End
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free